Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma-Reference-Cited by-同舟云学术

Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma

Published:2014-02-05 Issue:8 Volume:28 Page:1573-1585
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Dimopoulos M A,Leleu X,Palumbo A,Moreau P,Delforge M,Cavo M,Ludwig H,Morgan G J,Davies F E,Sonneveld P,Schey S A,Zweegman S,Hansson M,Weisel K,Mateos M V,Facon T,Miguel J F S

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/leu201460.pdf

Reference104 articles.

1. Kumar SK, Lee JH, Lahuerta JJ, Morgan G, Richardson PG, Crowley J et al. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia 2012; 26: 149–157.

2. Laubach J, Richardson P, Anderson K . Multiple myeloma. Ann Rev Med 2011; 62: 249–264.

3. Dimopoulos MA, Terpos E, Chanan-Khan A, Leung N, Ludwig H, Jagannath S et al. Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group. J Clin Oncol 2010; 28: 4976–4984.

4. Schütt P, Brandhorst D, Stellberg W, Poser M, Ebeling P, Müller S et al. Immune parameters in multiple myeloma patients: influence of treatment and correlation with opportunistic infections. Leuk Lymphoma 2006; 47: 1570–1582.

5. Wang X, Ottosson A, Ji C, Feng X, Nordenskjöld M, Henter JI et al. Proteasome inhibition induces apoptosis in primary human natural killer cells and suppresses NKp46-mediated cytotoxicity. Haematologica 2009; 94: 470–478.

Cited by 97 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Management of Adverse Events Associated with Pomalidomide-Based Combinations in Patients with Relapsed/Refractory Multiple Myeloma;Cancers;2024-02-29

2. Thrombotic Risk and Calculated Whole Blood Viscosity in a Cohort of Patients With New Diagnosis of Multiple Myeloma;Clinical and Applied Thrombosis/Hemostasis;2024-01

3. Antithrombotic utilization, adverse events, and associations with treatment outcomes in multiple myeloma: pooled analysis of three clinical trials;Therapeutic Advances in Medical Oncology;2024-01

4. Quantification of Pomalidomide Using Conventional and Eco-Friendly Stability-Indicating HPTLC Assays: A Contrast of Validation Parameters;ACS Omega;2023-08-07

5. Therapeutic strategies to enhance immune response induced by multiple myeloma cells;Frontiers in Immunology;2023-05-18